« Return to News | Clinical Intelligence

CTI Clinical Trial and Consulting Services, Galectin Therapeutics collaborate

Thursday, June 13, 2013 02:03 PM

CTI Clinical Trial and Consulting Services (CTI), an international drug and device development organization, will collaborate with Galectin Therapeutics on a first-in-man phase I clinical trial  of GR-MD-02 for treatment of non-alcoholic steatohepatitis (NASH) with advanced fibrosis.

The phase I clinical trial will be conducted in six centers in the U.S., all with experience in conducting liver disease trials. The enrollment and infusion of the first cohort will be completed by the end of the second quarter.

 “NASH affects between nine and 15 million people in the U.S., and is the third leading indication for liver transplantation,” said Lynn Fallon, executive vice president and president, consulting at CTI. “This trial will be critical to helping patients where there is currently no approved medical therapy.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.